Article

CURE New Issue Alert: Fall 2018

We've got a sneak peek at what’s inside our Fall 2018 issue.

Here’s a sneak peek at what’s inside our Fall 2018 issue:

Are you ready to find love after a cancer diagnosis? You’re not alone. Thousands of survivors want to date without having to explain themselves. Our cover story, In Sickness & In Health, shares dating websites designed specifically for people with cancer.

Next, fertility can sometimes be pushed to the side after a diagnosis is revealed. But Protecting Parenthood is possible. Another feature dives deeper into a new movement that aims to secure insurance coverage for patients who undergo fertility preservation before treatment.

And, about 2.8 million people in the United States serve as caregivers to someone with cancer. Inside this issue, we highlight Caring for the Caregivers. Learn about time management, coping mechanisms, decision-making and support group participation from those who have walked in your shoes.

Also, should men with prostate cancer have surgery to remove it? Hear from experts on both sides of the aisle.

To read these stories and more, visit curetoday.com/publications and click on the latest CURE cover.

Or, ensure you don’t miss a story when you subscribe to new issue alerts. Visit curetoday.com/email-profile for more information.

And, as always, thanks for reading.

Related Videos
CURE spoke with Dr. William C. Huang about what kind of team may be required to treat a patient with metastatic kidney cancer.
Image of man wearing baseball cap backwards.
Dr. Emre Yekedüz highlighted strategies that may improve patients' quality of life and mitigate treatment-related side effects in renal cell carcinoma.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Image of doctor with brown hair.
Image of man with black hair.
.Dr. Catherine Wu, chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston
Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.
Dr. Catherine Wu is chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston, Massachusetts.
Dr. Alan Tan is the GU Oncology Lead at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, as well as an associate professor in the Division of Hematology/Oncology at Vanderbilt University Medical Center and GU Executive Officer with the Alliance for Clinical Trials in Oncology.